nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydroxyurea—RRM1—Synthesis and interconversion of nucleotide di- and triphosphates—NME2—ovarian cancer	0.0287	0.104	CbGpPWpGaD
Hydroxyurea—RRM1—Nucleotide Metabolism—NME2—ovarian cancer	0.0275	0.0995	CbGpPWpGaD
Hydroxyurea—RRM2—Synthesis and interconversion of nucleotide di- and triphosphates—NME2—ovarian cancer	0.0236	0.0856	CbGpPWpGaD
Hydroxyurea—RRM2—Nucleotide Metabolism—NME2—ovarian cancer	0.0226	0.082	CbGpPWpGaD
Hydroxyurea—RRM2—myometrium—ovarian cancer	0.0109	0.0661	CbGeAlD
Hydroxyurea—RRM2—embryo—ovarian cancer	0.0105	0.0636	CbGeAlD
Hydroxyurea—RRM1—myometrium—ovarian cancer	0.00905	0.0549	CbGeAlD
Hydroxyurea—RRM1—Nucleotide metabolism—NME2—ovarian cancer	0.00888	0.0322	CbGpPWpGaD
Hydroxyurea—RRM2—uterine cervix—ovarian cancer	0.00848	0.0514	CbGeAlD
Hydroxyurea—RRM2—decidua—ovarian cancer	0.00808	0.049	CbGeAlD
Hydroxyurea—RRM2—endometrium—ovarian cancer	0.00767	0.0465	CbGeAlD
Hydroxyurea—RRM2—Nucleotide metabolism—NME2—ovarian cancer	0.00731	0.0265	CbGpPWpGaD
Hydroxyurea—RRM2—gonad—ovarian cancer	0.00711	0.0431	CbGeAlD
Hydroxyurea—RRM2—uterus—ovarian cancer	0.00707	0.0429	CbGeAlD
Hydroxyurea—RRM1—uterine cervix—ovarian cancer	0.00704	0.0427	CbGeAlD
Hydroxyurea—RRM1—decidua—ovarian cancer	0.00671	0.0407	CbGeAlD
Hydroxyurea—RRM1—endometrium—ovarian cancer	0.00637	0.0386	CbGeAlD
Hydroxyurea—RRM2—female reproductive system—ovarian cancer	0.00635	0.0385	CbGeAlD
Hydroxyurea—RRM2—bone marrow—ovarian cancer	0.006	0.0364	CbGeAlD
Hydroxyurea—RRM1—gonad—ovarian cancer	0.00591	0.0358	CbGeAlD
Hydroxyurea—RRM1—uterus—ovarian cancer	0.00587	0.0356	CbGeAlD
Hydroxyurea—RRM2—female gonad—ovarian cancer	0.00578	0.0351	CbGeAlD
Hydroxyurea—RRM2—vagina—ovarian cancer	0.00574	0.0348	CbGeAlD
Hydroxyurea—RRM1—Retinoblastoma (RB) in Cancer—BARD1—ovarian cancer	0.00573	0.0208	CbGpPWpGaD
Hydroxyurea—RRM2—G1/S-Specific Transcription—CCNE1—ovarian cancer	0.00571	0.0207	CbGpPWpGaD
Hydroxyurea—RRM2—G1/S-Specific Transcription—TYMS—ovarian cancer	0.00561	0.0203	CbGpPWpGaD
Hydroxyurea—RRM1—female reproductive system—ovarian cancer	0.00528	0.032	CbGeAlD
Hydroxyurea—RRM2—testis—ovarian cancer	0.00513	0.0311	CbGeAlD
Hydroxyurea—RRM1—bone marrow—ovarian cancer	0.00498	0.0302	CbGeAlD
Hydroxyurea—RRM1—E2F transcription factor network—RBL2—ovarian cancer	0.00484	0.0175	CbGpPWpGaD
Hydroxyurea—RRM1—female gonad—ovarian cancer	0.0048	0.0291	CbGeAlD
Hydroxyurea—RRM1—vagina—ovarian cancer	0.00477	0.0289	CbGeAlD
Hydroxyurea—RRM2—Retinoblastoma (RB) in Cancer—BARD1—ovarian cancer	0.00472	0.0171	CbGpPWpGaD
Hydroxyurea—RRM1—testis—ovarian cancer	0.00426	0.0258	CbGeAlD
Hydroxyurea—RRM1—Fluoropyrimidine Activity—TYMS—ovarian cancer	0.00401	0.0145	CbGpPWpGaD
Hydroxyurea—RRM2—E2F transcription factor network—RBL2—ovarian cancer	0.00399	0.0144	CbGpPWpGaD
Hydroxyurea—RRM2—lymph node—ovarian cancer	0.00372	0.0225	CbGeAlD
Hydroxyurea—RRM2—E2F mediated regulation of DNA replication—PPP2R1A—ovarian cancer	0.00362	0.0131	CbGpPWpGaD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	0.00343	0.0124	CbGpPWpGaD
Hydroxyurea—RRM2—E2F mediated regulation of DNA replication—CCNE1—ovarian cancer	0.00336	0.0122	CbGpPWpGaD
Hydroxyurea—RRM2—E2F mediated regulation of DNA replication—TYMS—ovarian cancer	0.0033	0.012	CbGpPWpGaD
Hydroxyurea—RRM2—Fluoropyrimidine Activity—TYMS—ovarian cancer	0.0033	0.012	CbGpPWpGaD
Hydroxyurea—RRM1—lymph node—ovarian cancer	0.00309	0.0187	CbGeAlD
Hydroxyurea—RRM1—Retinoblastoma (RB) in Cancer—SKP2—ovarian cancer	0.0028	0.0101	CbGpPWpGaD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	0.00279	0.0101	CbGpPWpGaD
Hydroxyurea—RRM1—E2F transcription factor network—BRCA1—ovarian cancer	0.00247	0.00894	CbGpPWpGaD
Hydroxyurea—RRM2—Mitotic G1-G1/S phases—RBL2—ovarian cancer	0.00244	0.00883	CbGpPWpGaD
Hydroxyurea—RRM2—Retinoblastoma (RB) in Cancer—SKP2—ovarian cancer	0.0023	0.00835	CbGpPWpGaD
Hydroxyurea—RRM1—E2F transcription factor network—CCNE1—ovarian cancer	0.00216	0.00783	CbGpPWpGaD
Hydroxyurea—RRM1—E2F transcription factor network—TYMS—ovarian cancer	0.00212	0.00769	CbGpPWpGaD
Hydroxyurea—RRM2—E2F transcription factor network—BRCA1—ovarian cancer	0.00203	0.00736	CbGpPWpGaD
Hydroxyurea—RRM1—Nucleotide metabolism—TYMS—ovarian cancer	0.00201	0.00729	CbGpPWpGaD
Hydroxyurea—CYP2D6—Codeine and Morphine Metabolism—ABCB1—ovarian cancer	0.00199	0.0072	CbGpPWpGaD
Hydroxyurea—RRM2—G1/S Transition—SKP2—ovarian cancer	0.00192	0.00697	CbGpPWpGaD
Hydroxyurea—RRM2—Cell Cycle—RSF1—ovarian cancer	0.0019	0.00687	CbGpPWpGaD
Hydroxyurea—RRM1—Retinoblastoma (RB) in Cancer—CCNE1—ovarian cancer	0.00188	0.00681	CbGpPWpGaD
Hydroxyurea—RRM1—Retinoblastoma (RB) in Cancer—TYMS—ovarian cancer	0.00184	0.00668	CbGpPWpGaD
Hydroxyurea—RRM2—E2F transcription factor network—CCNE1—ovarian cancer	0.00178	0.00645	CbGpPWpGaD
Hydroxyurea—RRM2—E2F transcription factor network—TYMS—ovarian cancer	0.00175	0.00633	CbGpPWpGaD
Hydroxyurea—RRM2—Nucleotide metabolism—TYMS—ovarian cancer	0.00166	0.00601	CbGpPWpGaD
Hydroxyurea—RRM2—Mitotic G1-G1/S phases—SKP2—ovarian cancer	0.00162	0.00587	CbGpPWpGaD
Hydroxyurea—CYP2D6—female reproductive system—ovarian cancer	0.00157	0.00951	CbGeAlD
Hydroxyurea—RRM2—Retinoblastoma (RB) in Cancer—CCNE1—ovarian cancer	0.00155	0.0056	CbGpPWpGaD
Hydroxyurea—RRM2—Retinoblastoma (RB) in Cancer—TYMS—ovarian cancer	0.00152	0.0055	CbGpPWpGaD
Hydroxyurea—CYP2D6—female gonad—ovarian cancer	0.00143	0.00865	CbGeAlD
Hydroxyurea—RRM2—G1/S Transition—PPP2R1A—ovarian cancer	0.00139	0.00504	CbGpPWpGaD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.00134	0.00484	CbGpPWpGaD
Hydroxyurea—RRM1—Fluoropyrimidine Activity—TP53—ovarian cancer	0.00133	0.00481	CbGpPWpGaD
Hydroxyurea—RRM2—G1/S Transition—CCNE1—ovarian cancer	0.00129	0.00468	CbGpPWpGaD
Hydroxyurea—RRM2—G1/S Transition—TYMS—ovarian cancer	0.00127	0.0046	CbGpPWpGaD
Hydroxyurea—CYP2D6—testis—ovarian cancer	0.00126	0.00767	CbGeAlD
Hydroxyurea—RRM2—Mitotic G1-G1/S phases—CCND2—ovarian cancer	0.00124	0.0045	CbGpPWpGaD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.00122	0.00442	CbGpPWpGaD
Hydroxyurea—RRM2—Mitotic G1-G1/S phases—PPP2R1A—ovarian cancer	0.00117	0.00425	CbGpPWpGaD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.00114	0.00414	CbGpPWpGaD
Hydroxyurea—RRM1—E2F transcription factor network—CDKN1B—ovarian cancer	0.00112	0.00406	CbGpPWpGaD
Hydroxyurea—CYP2D6—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.00112	0.00404	CbGpPWpGaD
Hydroxyurea—RRM2—Fluoropyrimidine Activity—TP53—ovarian cancer	0.00109	0.00396	CbGpPWpGaD
Hydroxyurea—RRM2—Mitotic G1-G1/S phases—CCNE1—ovarian cancer	0.00109	0.00394	CbGpPWpGaD
Hydroxyurea—RRM2—Mitotic G1-G1/S phases—TYMS—ovarian cancer	0.00107	0.00387	CbGpPWpGaD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.00103	0.00375	CbGpPWpGaD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.001	0.00363	CbGpPWpGaD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.001	0.00363	CbGpPWpGaD
Hydroxyurea—RRM2—Cell Cycle—RAD51C—ovarian cancer	0.000996	0.00361	CbGpPWpGaD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	0.000983	0.00356	CbGpPWpGaD
Hydroxyurea—RRM1—Retinoblastoma (RB) in Cancer—CDKN1B—ovarian cancer	0.000974	0.00353	CbGpPWpGaD
Hydroxyurea—RRM2—Cell Cycle, Mitotic—PPP1CC—ovarian cancer	0.000973	0.00353	CbGpPWpGaD
Hydroxyurea—RRM1—Retinoblastoma (RB) in Cancer—CCND1—ovarian cancer	0.000929	0.00337	CbGpPWpGaD
Hydroxyurea—RRM2—E2F transcription factor network—CDKN1B—ovarian cancer	0.000923	0.00334	CbGpPWpGaD
Hydroxyurea—RRM2—Cell Cycle, Mitotic—RBL2—ovarian cancer	0.000894	0.00324	CbGpPWpGaD
Hydroxyurea—RRM2—Cell Cycle—PPP1CC—ovarian cancer	0.00087	0.00315	CbGpPWpGaD
Hydroxyurea—CYP2D6—Melatonin metabolism and effects—CYP1B1—ovarian cancer	0.000862	0.00312	CbGpPWpGaD
Hydroxyurea—RRM1—E2F transcription factor network—MYC—ovarian cancer	0.000857	0.00311	CbGpPWpGaD
Hydroxyurea—RRM1—Metabolism—NME2—ovarian cancer	0.000806	0.00292	CbGpPWpGaD
Hydroxyurea—RRM2—Retinoblastoma (RB) in Cancer—CDKN1B—ovarian cancer	0.000802	0.00291	CbGpPWpGaD
Hydroxyurea—RRM2—Cell Cycle—RBL2—ovarian cancer	0.000799	0.0029	CbGpPWpGaD
Hydroxyurea—RRM2—Retinoblastoma (RB) in Cancer—CCND1—ovarian cancer	0.000765	0.00277	CbGpPWpGaD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.000764	0.00277	CbGpPWpGaD
Hydroxyurea—RRM1—Retinoblastoma (RB) in Cancer—MYC—ovarian cancer	0.000745	0.0027	CbGpPWpGaD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.000722	0.00262	CbGpPWpGaD
Hydroxyurea—RRM2—E2F transcription factor network—MYC—ovarian cancer	0.000706	0.00256	CbGpPWpGaD
Hydroxyurea—RRM2—G1/S Transition—CDKN1B—ovarian cancer	0.00067	0.00243	CbGpPWpGaD
Hydroxyurea—RRM2—Metabolism—NME2—ovarian cancer	0.000664	0.00241	CbGpPWpGaD
Hydroxyurea—RRM2—Retinoblastoma (RB) in Cancer—MYC—ovarian cancer	0.000614	0.00222	CbGpPWpGaD
Hydroxyurea—RRM1—Retinoblastoma (RB) in Cancer—TP53—ovarian cancer	0.000612	0.00222	CbGpPWpGaD
Hydroxyurea—RRM2—Cell Cycle, Mitotic—SKP2—ovarian cancer	0.000595	0.00215	CbGpPWpGaD
Hydroxyurea—RRM2—Mitotic G1-G1/S phases—CDKN1B—ovarian cancer	0.000564	0.00204	CbGpPWpGaD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	0.00056	0.00203	CbGpPWpGaD
Hydroxyurea—RRM2—Mitotic G1-G1/S phases—CCND1—ovarian cancer	0.000538	0.00195	CbGpPWpGaD
Hydroxyurea—RRM2—Cell Cycle—MLH1—ovarian cancer	0.000538	0.00195	CbGpPWpGaD
Hydroxyurea—Constipation—Topotecan—ovarian cancer	0.000534	0.000954	CcSEcCtD
Hydroxyurea—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.000532	0.000952	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle—SKP2—ovarian cancer	0.000532	0.00193	CbGpPWpGaD
Hydroxyurea—Decreased appetite—Melphalan—ovarian cancer	0.000531	0.00095	CcSEcCtD
Hydroxyurea—Infection—Vinorelbine—ovarian cancer	0.00053	0.000949	CcSEcCtD
Hydroxyurea—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000528	0.000944	CcSEcCtD
Hydroxyurea—Fatigue—Melphalan—ovarian cancer	0.000527	0.000942	CcSEcCtD
Hydroxyurea—Nervous system disorder—Vinorelbine—ovarian cancer	0.000524	0.000936	CcSEcCtD
Hydroxyurea—Rash maculo-papular—Epirubicin—ovarian cancer	0.000523	0.000935	CcSEcCtD
Hydroxyurea—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000523	0.000935	CcSEcCtD
Hydroxyurea—Pain—Melphalan—ovarian cancer	0.000523	0.000935	CcSEcCtD
Hydroxyurea—Neoplasm—Epirubicin—ovarian cancer	0.00052	0.00093	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—CYTB—ovarian cancer	0.00052	0.00188	CbGpPWpGaD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	0.000519	0.00188	CbGpPWpGaD
Hydroxyurea—Skin disorder—Vinorelbine—ovarian cancer	0.000519	0.000927	CcSEcCtD
Hydroxyurea—Hypersensitivity—Chlorambucil—ovarian cancer	0.000516	0.000924	CcSEcCtD
Hydroxyurea—Feeling abnormal—Topotecan—ovarian cancer	0.000514	0.00092	CcSEcCtD
Hydroxyurea—RRM2—G1/S Transition—MYC—ovarian cancer	0.000512	0.00186	CbGpPWpGaD
Hydroxyurea—Pulmonary oedema—Epirubicin—ovarian cancer	0.000512	0.000916	CcSEcCtD
Hydroxyurea—Anorexia—Vinorelbine—ovarian cancer	0.000509	0.00091	CcSEcCtD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	0.000509	0.00184	CbGpPWpGaD
Hydroxyurea—Skin exfoliation—Doxorubicin—ovarian cancer	0.000508	0.000909	CcSEcCtD
Hydroxyurea—Pancytopenia—Docetaxel—ovarian cancer	0.000508	0.000909	CcSEcCtD
Hydroxyurea—Haemoglobin—Paclitaxel—ovarian cancer	0.000508	0.000909	CcSEcCtD
Hydroxyurea—Haemorrhage—Paclitaxel—ovarian cancer	0.000505	0.000904	CcSEcCtD
Hydroxyurea—RRM2—Retinoblastoma (RB) in Cancer—TP53—ovarian cancer	0.000504	0.00183	CbGpPWpGaD
Hydroxyurea—Asthenia—Chlorambucil—ovarian cancer	0.000503	0.0009	CcSEcCtD
Hydroxyurea—Blood urea increased—Doxorubicin—ovarian cancer	0.000503	0.000899	CcSEcCtD
Hydroxyurea—Neutropenia—Docetaxel—ovarian cancer	0.0005	0.000895	CcSEcCtD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	0.000495	0.00179	CbGpPWpGaD
Hydroxyurea—Body temperature increased—Topotecan—ovarian cancer	0.000493	0.000882	CcSEcCtD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	0.00049	0.00178	CbGpPWpGaD
Hydroxyurea—Weight increased—Docetaxel—ovarian cancer	0.000487	0.000871	CcSEcCtD
Hydroxyurea—Rash maculo-papular—Doxorubicin—ovarian cancer	0.000484	0.000865	CcSEcCtD
Hydroxyurea—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000482	0.00175	CbGpPWpGaD
Hydroxyurea—Neoplasm—Doxorubicin—ovarian cancer	0.000481	0.000861	CcSEcCtD
Hydroxyurea—Diarrhoea—Chlorambucil—ovarian cancer	0.00048	0.000858	CcSEcCtD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	0.000478	0.00173	CbGpPWpGaD
Hydroxyurea—Infestation NOS—Docetaxel—ovarian cancer	0.000477	0.000853	CcSEcCtD
Hydroxyurea—Infestation—Docetaxel—ovarian cancer	0.000477	0.000853	CcSEcCtD
Hydroxyurea—Dyspnoea—Vinorelbine—ovarian cancer	0.000476	0.000851	CcSEcCtD
Hydroxyurea—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000475	0.00172	CbGpPWpGaD
Hydroxyurea—Pulmonary oedema—Doxorubicin—ovarian cancer	0.000474	0.000848	CcSEcCtD
Hydroxyurea—Neuropathy peripheral—Docetaxel—ovarian cancer	0.000468	0.000837	CcSEcCtD
Hydroxyurea—Stomatitis—Docetaxel—ovarian cancer	0.000465	0.000832	CcSEcCtD
Hydroxyurea—Hepatic failure—Epirubicin—ovarian cancer	0.000465	0.000831	CcSEcCtD
Hydroxyurea—Decreased appetite—Vinorelbine—ovarian cancer	0.000464	0.00083	CcSEcCtD
Hydroxyurea—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000461	0.000824	CcSEcCtD
Hydroxyurea—Fatigue—Vinorelbine—ovarian cancer	0.00046	0.000823	CcSEcCtD
Hydroxyurea—Hypersensitivity—Topotecan—ovarian cancer	0.00046	0.000822	CcSEcCtD
Hydroxyurea—Angiopathy—Paclitaxel—ovarian cancer	0.000459	0.00082	CcSEcCtD
Hydroxyurea—Constipation—Vinorelbine—ovarian cancer	0.000457	0.000816	CcSEcCtD
Hydroxyurea—Pain—Vinorelbine—ovarian cancer	0.000457	0.000816	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle, Mitotic—CCND2—ovarian cancer	0.000456	0.00165	CbGpPWpGaD
Hydroxyurea—RRM1—Metabolism—PPP1CC—ovarian cancer	0.000454	0.00165	CbGpPWpGaD
Hydroxyurea—RRM1—Metabolism—BRIP1—ovarian cancer	0.000454	0.00165	CbGpPWpGaD
Hydroxyurea—Chills—Paclitaxel—ovarian cancer	0.000453	0.000811	CcSEcCtD
Hydroxyurea—Renal failure acute—Epirubicin—ovarian cancer	0.000452	0.000809	CcSEcCtD
Hydroxyurea—Hepatobiliary disease—Docetaxel—ovarian cancer	0.000451	0.000807	CcSEcCtD
Hydroxyurea—Hypersensitivity—Melphalan—ovarian cancer	0.00045	0.000805	CcSEcCtD
Hydroxyurea—Asthenia—Topotecan—ovarian cancer	0.000448	0.000801	CcSEcCtD
Hydroxyurea—Alopecia—Paclitaxel—ovarian cancer	0.000447	0.000799	CcSEcCtD
Hydroxyurea—Vomiting—Chlorambucil—ovarian cancer	0.000446	0.000797	CcSEcCtD
Hydroxyurea—Erythema—Paclitaxel—ovarian cancer	0.00044	0.000787	CcSEcCtD
Hydroxyurea—Feeling abnormal—Vinorelbine—ovarian cancer	0.00044	0.000787	CcSEcCtD
Hydroxyurea—Asthenia—Melphalan—ovarian cancer	0.000438	0.000784	CcSEcCtD
Hydroxyurea—Dermatitis bullous—Epirubicin—ovarian cancer	0.000437	0.000782	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle—CHEK2—ovarian cancer	0.000435	0.00158	CbGpPWpGaD
Hydroxyurea—RRM2—Mitotic G1-G1/S phases—MYC—ovarian cancer	0.000432	0.00156	CbGpPWpGaD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	0.000432	0.00156	CbGpPWpGaD
Hydroxyurea—Haemoglobin—Docetaxel—ovarian cancer	0.000431	0.00077	CcSEcCtD
Hydroxyurea—Hepatic failure—Doxorubicin—ovarian cancer	0.00043	0.000769	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle, Mitotic—PPP2R1A—ovarian cancer	0.00043	0.00156	CbGpPWpGaD
Hydroxyurea—Haemorrhage—Docetaxel—ovarian cancer	0.000428	0.000766	CcSEcCtD
Hydroxyurea—RRM2—Metabolism—CYTB—ovarian cancer	0.000428	0.00155	CbGpPWpGaD
Hydroxyurea—Diarrhoea—Topotecan—ovarian cancer	0.000427	0.000764	CcSEcCtD
Hydroxyurea—Body temperature increased—Vinorelbine—ovarian cancer	0.000422	0.000755	CcSEcCtD
Hydroxyurea—Renal failure acute—Doxorubicin—ovarian cancer	0.000419	0.000749	CcSEcCtD
Hydroxyurea—Diarrhoea—Melphalan—ovarian cancer	0.000418	0.000748	CcSEcCtD
Hydroxyurea—Nausea—Chlorambucil—ovarian cancer	0.000416	0.000745	CcSEcCtD
Hydroxyurea—Dizziness—Topotecan—ovarian cancer	0.000413	0.000738	CcSEcCtD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	0.000408	0.00148	CbGpPWpGaD
Hydroxyurea—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000408	0.00073	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle—BRCA1—ovarian cancer	0.000408	0.00148	CbGpPWpGaD
Hydroxyurea—RRM2—Cell Cycle—CCND2—ovarian cancer	0.000408	0.00148	CbGpPWpGaD
Hydroxyurea—Anaemia—Paclitaxel—ovarian cancer	0.000407	0.000727	CcSEcCtD
Hydroxyurea—Dermatitis bullous—Doxorubicin—ovarian cancer	0.000404	0.000723	CcSEcCtD
Hydroxyurea—Face oedema—Epirubicin—ovarian cancer	0.000403	0.000721	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle, Mitotic—CCNE1—ovarian cancer	0.000399	0.00145	CbGpPWpGaD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	0.000397	0.00144	CbGpPWpGaD
Hydroxyurea—Vomiting—Topotecan—ovarian cancer	0.000397	0.00071	CcSEcCtD
Hydroxyurea—Malaise—Paclitaxel—ovarian cancer	0.000397	0.00071	CcSEcCtD
Hydroxyurea—Leukopenia—Paclitaxel—ovarian cancer	0.000394	0.000704	CcSEcCtD
Hydroxyurea—Rash—Topotecan—ovarian cancer	0.000393	0.000704	CcSEcCtD
Hydroxyurea—Hypersensitivity—Vinorelbine—ovarian cancer	0.000393	0.000703	CcSEcCtD
Hydroxyurea—Dermatitis—Topotecan—ovarian cancer	0.000393	0.000703	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle, Mitotic—TYMS—ovarian cancer	0.000392	0.00142	CbGpPWpGaD
Hydroxyurea—Blood creatinine increased—Epirubicin—ovarian cancer	0.000391	0.0007	CcSEcCtD
Hydroxyurea—Headache—Topotecan—ovarian cancer	0.000391	0.000699	CcSEcCtD
Hydroxyurea—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000391	0.00142	CbGpPWpGaD
Hydroxyurea—Angiopathy—Docetaxel—ovarian cancer	0.000389	0.000695	CcSEcCtD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	0.000389	0.00141	CbGpPWpGaD
Hydroxyurea—Vomiting—Melphalan—ovarian cancer	0.000389	0.000695	CcSEcCtD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	0.000389	0.00141	CbGpPWpGaD
Hydroxyurea—Rash—Melphalan—ovarian cancer	0.000385	0.000689	CcSEcCtD
Hydroxyurea—Dermatitis—Melphalan—ovarian cancer	0.000385	0.000688	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle—PPP2R1A—ovarian cancer	0.000384	0.00139	CbGpPWpGaD
Hydroxyurea—Chills—Docetaxel—ovarian cancer	0.000384	0.000687	CcSEcCtD
Hydroxyurea—Asthenia—Vinorelbine—ovarian cancer	0.000383	0.000685	CcSEcCtD
Hydroxyurea—Convulsion—Paclitaxel—ovarian cancer	0.000381	0.000682	CcSEcCtD
Hydroxyurea—Alopecia—Docetaxel—ovarian cancer	0.000379	0.000677	CcSEcCtD
Hydroxyurea—Breast disorder—Epirubicin—ovarian cancer	0.000377	0.000675	CcSEcCtD
Hydroxyurea—RRM2—Metabolism—PPP1CC—ovarian cancer	0.000374	0.00135	CbGpPWpGaD
Hydroxyurea—RRM2—Metabolism—BRIP1—ovarian cancer	0.000374	0.00135	CbGpPWpGaD
Hydroxyurea—Face oedema—Doxorubicin—ovarian cancer	0.000373	0.000667	CcSEcCtD
Hydroxyurea—Erythema—Docetaxel—ovarian cancer	0.000373	0.000667	CcSEcCtD
Hydroxyurea—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000372	0.000665	CcSEcCtD
Hydroxyurea—Nausea—Topotecan—ovarian cancer	0.000371	0.000663	CcSEcCtD
Hydroxyurea—Discomfort—Paclitaxel—ovarian cancer	0.00037	0.000662	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle—BRCA2—ovarian cancer	0.000369	0.00134	CbGpPWpGaD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	0.000367	0.00133	CbGpPWpGaD
Hydroxyurea—Diarrhoea—Vinorelbine—ovarian cancer	0.000365	0.000653	CcSEcCtD
Hydroxyurea—Nausea—Melphalan—ovarian cancer	0.000363	0.000649	CcSEcCtD
Hydroxyurea—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000362	0.000648	CcSEcCtD
Hydroxyurea—Oedema—Paclitaxel—ovarian cancer	0.000359	0.000642	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle—CCNE1—ovarian cancer	0.000357	0.00129	CbGpPWpGaD
Hydroxyurea—Infection—Paclitaxel—ovarian cancer	0.000357	0.000638	CcSEcCtD
Hydroxyurea—Pancreatitis—Epirubicin—ovarian cancer	0.000354	0.000633	CcSEcCtD
Hydroxyurea—Dizziness—Vinorelbine—ovarian cancer	0.000353	0.000631	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle, Mitotic—BIRC5—ovarian cancer	0.000353	0.00128	CbGpPWpGaD
Hydroxyurea—Nervous system disorder—Paclitaxel—ovarian cancer	0.000352	0.00063	CcSEcCtD
Hydroxyurea—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000352	0.000629	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle—TYMS—ovarian cancer	0.000351	0.00127	CbGpPWpGaD
Hydroxyurea—Breast disorder—Doxorubicin—ovarian cancer	0.000349	0.000625	CcSEcCtD
Hydroxyurea—Skin disorder—Paclitaxel—ovarian cancer	0.000349	0.000624	CcSEcCtD
Hydroxyurea—Anaemia—Docetaxel—ovarian cancer	0.000345	0.000616	CcSEcCtD
Hydroxyurea—Pancytopenia—Epirubicin—ovarian cancer	0.000343	0.000613	CcSEcCtD
Hydroxyurea—Anorexia—Paclitaxel—ovarian cancer	0.000342	0.000612	CcSEcCtD
Hydroxyurea—Vomiting—Vinorelbine—ovarian cancer	0.000339	0.000607	CcSEcCtD
Hydroxyurea—Dysuria—Epirubicin—ovarian cancer	0.000338	0.000604	CcSEcCtD
Hydroxyurea—Neutropenia—Epirubicin—ovarian cancer	0.000338	0.000604	CcSEcCtD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	0.000337	0.00122	CbGpPWpGaD
Hydroxyurea—Rash—Vinorelbine—ovarian cancer	0.000337	0.000602	CcSEcCtD
Hydroxyurea—Dermatitis—Vinorelbine—ovarian cancer	0.000336	0.000601	CcSEcCtD
Hydroxyurea—Headache—Vinorelbine—ovarian cancer	0.000334	0.000598	CcSEcCtD
Hydroxyurea—Leukopenia—Docetaxel—ovarian cancer	0.000334	0.000597	CcSEcCtD
Hydroxyurea—Weight increased—Epirubicin—ovarian cancer	0.000329	0.000588	CcSEcCtD
Hydroxyurea—Pancreatitis—Doxorubicin—ovarian cancer	0.000327	0.000586	CcSEcCtD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	0.000326	0.00118	CbGpPWpGaD
Hydroxyurea—Convulsion—Docetaxel—ovarian cancer	0.000323	0.000578	CcSEcCtD
Hydroxyurea—Drowsiness—Epirubicin—ovarian cancer	0.000322	0.000576	CcSEcCtD
Hydroxyurea—Infestation NOS—Epirubicin—ovarian cancer	0.000322	0.000576	CcSEcCtD
Hydroxyurea—Infestation—Epirubicin—ovarian cancer	0.000322	0.000576	CcSEcCtD
Hydroxyurea—Dyspnoea—Paclitaxel—ovarian cancer	0.00032	0.000573	CcSEcCtD
Hydroxyurea—Somnolence—Paclitaxel—ovarian cancer	0.000319	0.000571	CcSEcCtD
Hydroxyurea—Pancytopenia—Doxorubicin—ovarian cancer	0.000317	0.000567	CcSEcCtD
Hydroxyurea—Nausea—Vinorelbine—ovarian cancer	0.000317	0.000567	CcSEcCtD
Hydroxyurea—Dyspepsia—Paclitaxel—ovarian cancer	0.000316	0.000565	CcSEcCtD
Hydroxyurea—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000316	0.000564	CcSEcCtD
Hydroxyurea—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000315	0.000564	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle—BIRC5—ovarian cancer	0.000315	0.00114	CbGpPWpGaD
Hydroxyurea—Stomatitis—Epirubicin—ovarian cancer	0.000314	0.000561	CcSEcCtD
Hydroxyurea—Dysuria—Doxorubicin—ovarian cancer	0.000312	0.000559	CcSEcCtD
Hydroxyurea—Neutropenia—Doxorubicin—ovarian cancer	0.000312	0.000559	CcSEcCtD
Hydroxyurea—Decreased appetite—Paclitaxel—ovarian cancer	0.000312	0.000558	CcSEcCtD
Hydroxyurea—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00031	0.000554	CcSEcCtD
Hydroxyurea—Fatigue—Paclitaxel—ovarian cancer	0.00031	0.000554	CcSEcCtD
Hydroxyurea—Pain—Paclitaxel—ovarian cancer	0.000307	0.000549	CcSEcCtD
Hydroxyurea—Constipation—Paclitaxel—ovarian cancer	0.000307	0.000549	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle—TERT—ovarian cancer	0.000305	0.00111	CbGpPWpGaD
Hydroxyurea—RRM1—Metabolism—YAP1—ovarian cancer	0.000305	0.0011	CbGpPWpGaD
Hydroxyurea—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000304	0.000544	CcSEcCtD
Hydroxyurea—Oedema—Docetaxel—ovarian cancer	0.000304	0.000544	CcSEcCtD
Hydroxyurea—Weight increased—Doxorubicin—ovarian cancer	0.000304	0.000544	CcSEcCtD
Hydroxyurea—Infection—Docetaxel—ovarian cancer	0.000302	0.000541	CcSEcCtD
Hydroxyurea—Nervous system disorder—Docetaxel—ovarian cancer	0.000298	0.000534	CcSEcCtD
Hydroxyurea—Thrombocytopenia—Docetaxel—ovarian cancer	0.000298	0.000533	CcSEcCtD
Hydroxyurea—Infestation—Doxorubicin—ovarian cancer	0.000298	0.000533	CcSEcCtD
Hydroxyurea—Infestation NOS—Doxorubicin—ovarian cancer	0.000298	0.000533	CcSEcCtD
Hydroxyurea—Drowsiness—Doxorubicin—ovarian cancer	0.000298	0.000533	CcSEcCtD
Hydroxyurea—Feeling abnormal—Paclitaxel—ovarian cancer	0.000296	0.000529	CcSEcCtD
Hydroxyurea—Skin disorder—Docetaxel—ovarian cancer	0.000296	0.000529	CcSEcCtD
Hydroxyurea—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000292	0.000522	CcSEcCtD
Hydroxyurea—Haemoglobin—Epirubicin—ovarian cancer	0.00029	0.000519	CcSEcCtD
Hydroxyurea—Stomatitis—Doxorubicin—ovarian cancer	0.00029	0.000519	CcSEcCtD
Hydroxyurea—Anorexia—Docetaxel—ovarian cancer	0.00029	0.000519	CcSEcCtD
Hydroxyurea—Haemorrhage—Epirubicin—ovarian cancer	0.000289	0.000517	CcSEcCtD
Hydroxyurea—Body temperature increased—Paclitaxel—ovarian cancer	0.000284	0.000508	CcSEcCtD
Hydroxyurea—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000282	0.000504	CcSEcCtD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	0.000275	0.000998	CbGpPWpGaD
Hydroxyurea—Dyspnoea—Docetaxel—ovarian cancer	0.000271	0.000485	CcSEcCtD
Hydroxyurea—Somnolence—Docetaxel—ovarian cancer	0.000271	0.000484	CcSEcCtD
Hydroxyurea—Haemoglobin—Doxorubicin—ovarian cancer	0.000269	0.000481	CcSEcCtD
Hydroxyurea—Dyspepsia—Docetaxel—ovarian cancer	0.000268	0.000479	CcSEcCtD
Hydroxyurea—Haemorrhage—Doxorubicin—ovarian cancer	0.000267	0.000478	CcSEcCtD
Hydroxyurea—Decreased appetite—Docetaxel—ovarian cancer	0.000265	0.000473	CcSEcCtD
Hydroxyurea—Hypersensitivity—Paclitaxel—ovarian cancer	0.000265	0.000473	CcSEcCtD
Hydroxyurea—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000263	0.00047	CcSEcCtD
Hydroxyurea—Fatigue—Docetaxel—ovarian cancer	0.000262	0.000469	CcSEcCtD
Hydroxyurea—Angiopathy—Epirubicin—ovarian cancer	0.000262	0.000469	CcSEcCtD
Hydroxyurea—Pain—Docetaxel—ovarian cancer	0.00026	0.000465	CcSEcCtD
Hydroxyurea—Constipation—Docetaxel—ovarian cancer	0.00026	0.000465	CcSEcCtD
Hydroxyurea—Chills—Epirubicin—ovarian cancer	0.000259	0.000464	CcSEcCtD
Hydroxyurea—Asthenia—Paclitaxel—ovarian cancer	0.000258	0.000461	CcSEcCtD
Hydroxyurea—Alopecia—Epirubicin—ovarian cancer	0.000255	0.000457	CcSEcCtD
Hydroxyurea—Erythema—Epirubicin—ovarian cancer	0.000252	0.00045	CcSEcCtD
Hydroxyurea—RRM2—Metabolism—YAP1—ovarian cancer	0.000251	0.000909	CbGpPWpGaD
Hydroxyurea—Feeling abnormal—Docetaxel—ovarian cancer	0.000251	0.000449	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—FASN—ovarian cancer	0.000248	0.0009	CbGpPWpGaD
Hydroxyurea—Diarrhoea—Paclitaxel—ovarian cancer	0.000246	0.000439	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—SLC5A5—ovarian cancer	0.000244	0.000885	CbGpPWpGaD
Hydroxyurea—Angiopathy—Doxorubicin—ovarian cancer	0.000243	0.000434	CcSEcCtD
Hydroxyurea—Body temperature increased—Docetaxel—ovarian cancer	0.000241	0.00043	CcSEcCtD
Hydroxyurea—Chills—Doxorubicin—ovarian cancer	0.00024	0.000429	CcSEcCtD
Hydroxyurea—Dizziness—Paclitaxel—ovarian cancer	0.000237	0.000425	CcSEcCtD
Hydroxyurea—Alopecia—Doxorubicin—ovarian cancer	0.000236	0.000423	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—SLC2A1—ovarian cancer	0.000236	0.000855	CbGpPWpGaD
Hydroxyurea—Ill-defined disorder—Epirubicin—ovarian cancer	0.000233	0.000417	CcSEcCtD
Hydroxyurea—Erythema—Doxorubicin—ovarian cancer	0.000233	0.000416	CcSEcCtD
Hydroxyurea—Anaemia—Epirubicin—ovarian cancer	0.000232	0.000416	CcSEcCtD
Hydroxyurea—Vomiting—Paclitaxel—ovarian cancer	0.000228	0.000408	CcSEcCtD
Hydroxyurea—Malaise—Epirubicin—ovarian cancer	0.000227	0.000406	CcSEcCtD
Hydroxyurea—Rash—Paclitaxel—ovarian cancer	0.000226	0.000405	CcSEcCtD
Hydroxyurea—Dermatitis—Paclitaxel—ovarian cancer	0.000226	0.000405	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—CYP1B1—ovarian cancer	0.000226	0.000819	CbGpPWpGaD
Hydroxyurea—Leukopenia—Epirubicin—ovarian cancer	0.000225	0.000403	CcSEcCtD
Hydroxyurea—Headache—Paclitaxel—ovarian cancer	0.000225	0.000402	CcSEcCtD
Hydroxyurea—Hypersensitivity—Docetaxel—ovarian cancer	0.000224	0.000401	CcSEcCtD
Hydroxyurea—Asthenia—Docetaxel—ovarian cancer	0.000218	0.000391	CcSEcCtD
Hydroxyurea—Convulsion—Epirubicin—ovarian cancer	0.000218	0.00039	CcSEcCtD
Hydroxyurea—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000216	0.000386	CcSEcCtD
Hydroxyurea—Anaemia—Doxorubicin—ovarian cancer	0.000215	0.000385	CcSEcCtD
Hydroxyurea—Nausea—Paclitaxel—ovarian cancer	0.000213	0.000381	CcSEcCtD
Hydroxyurea—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000213	0.00038	CcSEcCtD
Hydroxyurea—Discomfort—Epirubicin—ovarian cancer	0.000212	0.000378	CcSEcCtD
Hydroxyurea—Malaise—Doxorubicin—ovarian cancer	0.00021	0.000375	CcSEcCtD
Hydroxyurea—Leukopenia—Doxorubicin—ovarian cancer	0.000208	0.000373	CcSEcCtD
Hydroxyurea—Diarrhoea—Docetaxel—ovarian cancer	0.000208	0.000372	CcSEcCtD
Hydroxyurea—CYP2D6—Biological oxidations—CYP1B1—ovarian cancer	0.000207	0.000752	CbGpPWpGaD
Hydroxyurea—RRM2—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	0.000207	0.00075	CbGpPWpGaD
Hydroxyurea—Oedema—Epirubicin—ovarian cancer	0.000205	0.000367	CcSEcCtD
Hydroxyurea—CYP2D6—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000205	0.000741	CbGpPWpGaD
Hydroxyurea—RRM2—Metabolism—FASN—ovarian cancer	0.000204	0.000741	CbGpPWpGaD
Hydroxyurea—Infection—Epirubicin—ovarian cancer	0.000204	0.000365	CcSEcCtD
Hydroxyurea—Convulsion—Doxorubicin—ovarian cancer	0.000202	0.000361	CcSEcCtD
Hydroxyurea—Nervous system disorder—Epirubicin—ovarian cancer	0.000201	0.00036	CcSEcCtD
Hydroxyurea—Dizziness—Docetaxel—ovarian cancer	0.000201	0.00036	CcSEcCtD
Hydroxyurea—RRM2—Metabolism—SLC5A5—ovarian cancer	0.000201	0.000729	CbGpPWpGaD
Hydroxyurea—Thrombocytopenia—Epirubicin—ovarian cancer	0.000201	0.000359	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—PPP2R1A—ovarian cancer	0.000201	0.000727	CbGpPWpGaD
Hydroxyurea—Skin disorder—Epirubicin—ovarian cancer	0.000199	0.000357	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle, Mitotic—CCND1—ovarian cancer	0.000197	0.000715	CbGpPWpGaD
Hydroxyurea—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000197	0.000352	CcSEcCtD
Hydroxyurea—Discomfort—Doxorubicin—ovarian cancer	0.000196	0.00035	CcSEcCtD
Hydroxyurea—Anorexia—Epirubicin—ovarian cancer	0.000196	0.00035	CcSEcCtD
Hydroxyurea—RRM2—Metabolism—SLC2A1—ovarian cancer	0.000194	0.000704	CbGpPWpGaD
Hydroxyurea—Vomiting—Docetaxel—ovarian cancer	0.000194	0.000346	CcSEcCtD
Hydroxyurea—Rash—Docetaxel—ovarian cancer	0.000192	0.000343	CcSEcCtD
Hydroxyurea—Dermatitis—Docetaxel—ovarian cancer	0.000192	0.000343	CcSEcCtD
Hydroxyurea—Headache—Docetaxel—ovarian cancer	0.000191	0.000341	CcSEcCtD
Hydroxyurea—Oedema—Doxorubicin—ovarian cancer	0.00019	0.00034	CcSEcCtD
Hydroxyurea—Infection—Doxorubicin—ovarian cancer	0.000189	0.000337	CcSEcCtD
Hydroxyurea—Nervous system disorder—Doxorubicin—ovarian cancer	0.000186	0.000333	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—ABCB1—ovarian cancer	0.000186	0.000675	CbGpPWpGaD
Hydroxyurea—RRM2—Metabolism—CYP1B1—ovarian cancer	0.000186	0.000675	CbGpPWpGaD
Hydroxyurea—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000186	0.000333	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle—CDKN1B—ovarian cancer	0.000185	0.00067	CbGpPWpGaD
Hydroxyurea—Skin disorder—Doxorubicin—ovarian cancer	0.000184	0.00033	CcSEcCtD
Hydroxyurea—Dyspnoea—Epirubicin—ovarian cancer	0.000183	0.000327	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—TYMS—ovarian cancer	0.000183	0.000663	CbGpPWpGaD
Hydroxyurea—Somnolence—Epirubicin—ovarian cancer	0.000182	0.000326	CcSEcCtD
Hydroxyurea—Anorexia—Doxorubicin—ovarian cancer	0.000181	0.000324	CcSEcCtD
Hydroxyurea—Nausea—Docetaxel—ovarian cancer	0.000181	0.000323	CcSEcCtD
Hydroxyurea—Dyspepsia—Epirubicin—ovarian cancer	0.000181	0.000323	CcSEcCtD
Hydroxyurea—Decreased appetite—Epirubicin—ovarian cancer	0.000178	0.000319	CcSEcCtD
Hydroxyurea—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000177	0.000317	CcSEcCtD
Hydroxyurea—Fatigue—Epirubicin—ovarian cancer	0.000177	0.000317	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle—CCND1—ovarian cancer	0.000177	0.000639	CbGpPWpGaD
Hydroxyurea—Constipation—Epirubicin—ovarian cancer	0.000176	0.000314	CcSEcCtD
Hydroxyurea—Pain—Epirubicin—ovarian cancer	0.000176	0.000314	CcSEcCtD
Hydroxyurea—Dyspnoea—Doxorubicin—ovarian cancer	0.000169	0.000303	CcSEcCtD
Hydroxyurea—Feeling abnormal—Epirubicin—ovarian cancer	0.000169	0.000303	CcSEcCtD
Hydroxyurea—Somnolence—Doxorubicin—ovarian cancer	0.000169	0.000302	CcSEcCtD
Hydroxyurea—Dyspepsia—Doxorubicin—ovarian cancer	0.000167	0.000299	CcSEcCtD
Hydroxyurea—RRM2—Metabolism—PPP2R1A—ovarian cancer	0.000165	0.000598	CbGpPWpGaD
Hydroxyurea—Decreased appetite—Doxorubicin—ovarian cancer	0.000165	0.000295	CcSEcCtD
Hydroxyurea—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000164	0.000293	CcSEcCtD
Hydroxyurea—Fatigue—Doxorubicin—ovarian cancer	0.000164	0.000293	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle, Mitotic—MAPK3—ovarian cancer	0.000163	0.00059	CbGpPWpGaD
Hydroxyurea—Pain—Doxorubicin—ovarian cancer	0.000162	0.000291	CcSEcCtD
Hydroxyurea—Constipation—Doxorubicin—ovarian cancer	0.000162	0.000291	CcSEcCtD
Hydroxyurea—Body temperature increased—Epirubicin—ovarian cancer	0.000162	0.00029	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle, Mitotic—MYC—ovarian cancer	0.000158	0.000574	CbGpPWpGaD
Hydroxyurea—Feeling abnormal—Doxorubicin—ovarian cancer	0.000157	0.00028	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle, Mitotic—MAPK1—ovarian cancer	0.000155	0.000561	CbGpPWpGaD
Hydroxyurea—RRM2—Metabolism—ABCB1—ovarian cancer	0.000153	0.000556	CbGpPWpGaD
Hydroxyurea—Hypersensitivity—Epirubicin—ovarian cancer	0.000151	0.000271	CcSEcCtD
Hydroxyurea—RRM2—Metabolism—TYMS—ovarian cancer	0.000151	0.000546	CbGpPWpGaD
Hydroxyurea—Body temperature increased—Doxorubicin—ovarian cancer	0.00015	0.000269	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—CAV1—ovarian cancer	0.000147	0.000534	CbGpPWpGaD
Hydroxyurea—Asthenia—Epirubicin—ovarian cancer	0.000147	0.000263	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle—MAPK3—ovarian cancer	0.000146	0.000527	CbGpPWpGaD
Hydroxyurea—RRM2—Cell Cycle—MYC—ovarian cancer	0.000142	0.000513	CbGpPWpGaD
Hydroxyurea—Diarrhoea—Epirubicin—ovarian cancer	0.00014	0.000251	CcSEcCtD
Hydroxyurea—Hypersensitivity—Doxorubicin—ovarian cancer	0.00014	0.00025	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle—MAPK1—ovarian cancer	0.000139	0.000502	CbGpPWpGaD
Hydroxyurea—Asthenia—Doxorubicin—ovarian cancer	0.000136	0.000244	CcSEcCtD
Hydroxyurea—Dizziness—Epirubicin—ovarian cancer	0.000136	0.000243	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—PIK3CG—ovarian cancer	0.000134	0.000486	CbGpPWpGaD
Hydroxyurea—Vomiting—Epirubicin—ovarian cancer	0.000131	0.000233	CcSEcCtD
Hydroxyurea—Diarrhoea—Doxorubicin—ovarian cancer	0.00013	0.000232	CcSEcCtD
Hydroxyurea—Rash—Epirubicin—ovarian cancer	0.000129	0.000231	CcSEcCtD
Hydroxyurea—Dermatitis—Epirubicin—ovarian cancer	0.000129	0.000231	CcSEcCtD
Hydroxyurea—Headache—Epirubicin—ovarian cancer	0.000129	0.00023	CcSEcCtD
Hydroxyurea—CYP2D6—Metabolism—NME2—ovarian cancer	0.000127	0.000458	CbGpPWpGaD
Hydroxyurea—Dizziness—Doxorubicin—ovarian cancer	0.000126	0.000225	CcSEcCtD
Hydroxyurea—Nausea—Epirubicin—ovarian cancer	0.000122	0.000218	CcSEcCtD
Hydroxyurea—RRM2—Metabolism—CAV1—ovarian cancer	0.000121	0.00044	CbGpPWpGaD
Hydroxyurea—Vomiting—Doxorubicin—ovarian cancer	0.000121	0.000216	CcSEcCtD
Hydroxyurea—Rash—Doxorubicin—ovarian cancer	0.00012	0.000214	CcSEcCtD
Hydroxyurea—Dermatitis—Doxorubicin—ovarian cancer	0.00012	0.000214	CcSEcCtD
Hydroxyurea—Headache—Doxorubicin—ovarian cancer	0.000119	0.000213	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—PIK3CD—ovarian cancer	0.000118	0.000428	CbGpPWpGaD
Hydroxyurea—RRM2—Cell Cycle—TP53—ovarian cancer	0.000116	0.000421	CbGpPWpGaD
Hydroxyurea—Nausea—Doxorubicin—ovarian cancer	0.000113	0.000202	CcSEcCtD
Hydroxyurea—RRM2—Metabolism—PIK3CG—ovarian cancer	0.000111	0.0004	CbGpPWpGaD
Hydroxyurea—RRM1—Metabolism—PIK3CB—ovarian cancer	0.000103	0.000373	CbGpPWpGaD
Hydroxyurea—RRM2—Metabolism—PIK3CD—ovarian cancer	9.72e-05	0.000352	CbGpPWpGaD
Hydroxyurea—RRM1—Metabolism—PTEN—ovarian cancer	8.89e-05	0.000322	CbGpPWpGaD
Hydroxyurea—RRM2—Metabolism—PIK3CB—ovarian cancer	8.47e-05	0.000307	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—CYTB—ovarian cancer	8.15e-05	0.000295	CbGpPWpGaD
Hydroxyurea—RRM2—Metabolism—PTEN—ovarian cancer	7.32e-05	0.000265	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—PPP1CC—ovarian cancer	7.13e-05	0.000258	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—BRIP1—ovarian cancer	7.13e-05	0.000258	CbGpPWpGaD
Hydroxyurea—RRM1—Metabolism—PIK3CA—ovarian cancer	6.27e-05	0.000227	CbGpPWpGaD
Hydroxyurea—RRM2—Metabolism—PIK3CA—ovarian cancer	5.16e-05	0.000187	CbGpPWpGaD
Hydroxyurea—RRM1—Metabolism—AKT1—ovarian cancer	5.12e-05	0.000186	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—YAP1—ovarian cancer	4.78e-05	0.000173	CbGpPWpGaD
Hydroxyurea—RRM2—Metabolism—AKT1—ovarian cancer	4.22e-05	0.000153	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—FASN—ovarian cancer	3.9e-05	0.000141	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—SLC5A5—ovarian cancer	3.83e-05	0.000139	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—SLC2A1—ovarian cancer	3.7e-05	0.000134	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—CYP1B1—ovarian cancer	3.55e-05	0.000129	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	3.15e-05	0.000114	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—ABCB1—ovarian cancer	2.92e-05	0.000106	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—TYMS—ovarian cancer	2.87e-05	0.000104	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—CAV1—ovarian cancer	2.31e-05	8.38e-05	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—PIK3CG—ovarian cancer	2.11e-05	7.63e-05	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.85e-05	6.71e-05	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.61e-05	5.85e-05	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—PTEN—ovarian cancer	1.39e-05	5.05e-05	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—PIK3CA—ovarian cancer	9.84e-06	3.56e-05	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—AKT1—ovarian cancer	8.04e-06	2.91e-05	CbGpPWpGaD
